Skip to main content

Mid Year Update

Since we are not quite at the midpoint of 2020, let’s take the opportunity to refocus on a few of YMC’s latest whitepapers and app notes.

YMC for Biologics — Published with the help of Chemical & Engineering News, this whitepaper focuses on the analysis and purification of Biologics. 

Hybrid Silica Advantages — This whitepaper appeared in LCGC Magazine. In it, we explore how hybrid silica can help to make HPLC method development a little easier.

CBD and Melatonin Analysis & CBD Purification — CBD continues to be of high interest to many of our customers for its potential uses and benefits. YMC can help at any scale, from method development through industrial scale production.

Those who are interested in learning more can contact us directly at info@ymcamerica.com. We’re also accepting orders for all HPLC and UHPLC columns, including Triart C-18, Triart Bio C4, and more. Don’t hesitate to contact us today with any questions. 

Posted on June 2, 2020.

Related Posts

September 4, 2026

YMC America Brings U.S.-Supplied ASME U-Stamped DAC Columns to Pharmaceutical Manufacturers

YMC America will be the First U.S.-Based Supplier of ASME U-Stamped DAC Columns. The company’s DAC columns support pharmaceutical and biopharmaceutical customers from process development through commercial production. Systems are used in laboratory, pilot, and production-scale chromatography applications, including purification processes for peptides, oligonucleotides, and small-molecule APIs.

September 9, 2026

Tecnologias Analíticas para Peptídeos Terapêuticos- Portuguese

Os peptídeos terapêuticos são uma classe emergente de insumos farmacêuticos ativos que, juntamente com outras classes de bioprodutos, vêm despertando grande interesse devido às suas vantagens únicas.

September 9, 2026

Tecnologías Analíticas para Péptidos Terapéuticos- Spanish

El primer péptido estudiado en este campo fue la insulina, una cadena de 51 aminoácidos que fue aislada originalmente en 1921 por Frederick Banting y Charles Best y que posteriormente se convirtió en el primer péptido disponible comercialmente (1923). Actualmente, existe una extensa lista de péptidos disponibles comercialmente en el mercado, incluidos los conocidos análogos de GLP-1, como liraglutida, semaglutida y tirzepatida.

Designed and developed by